140 related articles for article (PubMed ID: 31630573)
1. Current Status of Angiotensin Receptor Blocker Recalls.
Gunasekaran PM; Chertow GM; Bhalla V; Byrd JB
Hypertension; 2019 Dec; 74(6):1275-1278. PubMed ID: 31630573
[TBL] [Abstract][Full Text] [Related]
2. Neoplasm Reports in Food and Drug Administration Adverse Event Reporting System Following Angiotensin Receptor Blocker Recalls.
Cohen Sedgh R; Moon J; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2021 Aug; 14(8):e007476. PubMed ID: 34380327
[TBL] [Abstract][Full Text] [Related]
3. A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization - results from IQVIA™ Disease Analyzer Germany.
Hedenmalm K; Quinten C; Kurz X; Bradley M; Lee H; Eworuke E
Eur J Clin Pharmacol; 2023 Jun; 79(6):849-858. PubMed ID: 37095262
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin Receptor Blockers and the Risk of Cancer: Insights from Clinical Trials and Recent Drug Recalls.
Berrido AM; Byrd JB
Curr Hypertens Rep; 2020 Feb; 22(3):20. PubMed ID: 32114653
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
6. Losartan/hydrochlorothiazide combination therapy surpasses high-dose angiotensin receptor blocker in the reduction of morning home blood pressure in patients with morning hypertension.
Hanayama Y; Uchida HA; Nakamura Y; Makino H
Acta Med Okayama; 2012; 66(6):449-59. PubMed ID: 23254579
[TBL] [Abstract][Full Text] [Related]
7. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
Bharate SS
J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
[TBL] [Abstract][Full Text] [Related]
8. Nitrosamine Impurities in Angiotensin Receptor Blockers.
Shephard EA; Nawarskas JJ
Cardiol Rev; 2020; 28(5):262-265. PubMed ID: 32467427
[TBL] [Abstract][Full Text] [Related]
9. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
11. The velocity of antihypertensive effect of losartan/hydrochlorothiazide and angiotensin II receptor blocker.
Metoki H; Ohkubo T; Kikuya M; Asayama K; Inoue R; Obara T; Hirose T; Sato M; Hashimoto T; Imai Y;
J Hypertens; 2012 Jul; 30(7):1478-86. PubMed ID: 22573119
[TBL] [Abstract][Full Text] [Related]
12. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
[TBL] [Abstract][Full Text] [Related]
13. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
[TBL] [Abstract][Full Text] [Related]
14. Losartan associated anaphylaxis and angioneurotic oedema.
Kazim SF; Shahid M
J Pak Med Assoc; 2010 Aug; 60(8):685-6. PubMed ID: 20726206
[TBL] [Abstract][Full Text] [Related]
15. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.
Hesse U; Godman B; Petzold M; Martin A; Malmström RE
Appl Health Econ Health Policy; 2013 Dec; 11(6):677-85. PubMed ID: 24105097
[TBL] [Abstract][Full Text] [Related]
16. Type 2 diabetes mellitus complicated by hypertension in Japanese patients: switching treatment from high-dose angiotensin II receptor blockers to losartan plus hydrochlorothiazide.
Yamamoto S; Okada Y; Mori H; Nishida K; Uriu K; Tanaka Y
Intern Med; 2014; 53(12):1283-9. PubMed ID: 24930646
[TBL] [Abstract][Full Text] [Related]
17. Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States.
Desai RJ; Sarpatwari A; Gautam N; Lii J; Fischer MA; Gagne JJ
JAMA; 2020 Jan; 323(1):87-89. PubMed ID: 31910271
[TBL] [Abstract][Full Text] [Related]
18. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year.
Sato N; Saijo Y; Sasagawa Y; Morimoto H; Takeuchi T; Sano H; Koyama S; Takehara N; Morita K; Sumitomo K; Maruyama J; Kikuchi K; Hasebe N;
J Hypertens; 2013 Jun; 31(6):1245-55. PubMed ID: 23492647
[TBL] [Abstract][Full Text] [Related]
19. Losartan and renal transplantation.
Horn S; Holzer H; Horina J
Lancet; 1998 Jan; 351(9096):111. PubMed ID: 9439500
[No Abstract] [Full Text] [Related]
20. Fetal toxic effects and angiotensin-II-receptor antagonists.
Martinovic J; Benachi A; Laurent N; Daikha-Dahmane F; Gubler MC
Lancet; 2001 Jul; 358(9277):241-2. PubMed ID: 11480433
[No Abstract] [Full Text] [Related]
[Next] [New Search]
